GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » POINT Biopharma Global Inc (NAS:PNT) » Definitions » EV-to-EBITDA

POINT Biopharma Global (POINT Biopharma Global) EV-to-EBITDA : 9.09 (As of May. 25, 2024)


View and export this data going back to 2020. Start your Free Trial

What is POINT Biopharma Global EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, POINT Biopharma Global's enterprise value is $1,003.6 Mil. POINT Biopharma Global's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $110.4 Mil. Therefore, POINT Biopharma Global's EV-to-EBITDA for today is 9.09.

The historical rank and industry rank for POINT Biopharma Global's EV-to-EBITDA or its related term are showing as below:

PNT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.84   Med: 4.52   Max: 10.5
Current: 9.09

During the past 3 years, the highest EV-to-EBITDA of POINT Biopharma Global was 10.50. The lowest was 1.84. And the median was 4.52.

PNT's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.67 vs PNT: 9.09

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), POINT Biopharma Global's stock price is $12.50. POINT Biopharma Global's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $1.100. Therefore, POINT Biopharma Global's PE Ratio for today is 11.36.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


POINT Biopharma Global EV-to-EBITDA Historical Data

The historical data trend for POINT Biopharma Global's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

POINT Biopharma Global EV-to-EBITDA Chart

POINT Biopharma Global Annual Data
Trend Dec20 Dec21 Dec22
EV-to-EBITDA
- -5.83 1.93

POINT Biopharma Global Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.49 1.93 2.79 4.71 3.42

Competitive Comparison of POINT Biopharma Global's EV-to-EBITDA

For the Biotechnology subindustry, POINT Biopharma Global's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


POINT Biopharma Global's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, POINT Biopharma Global's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where POINT Biopharma Global's EV-to-EBITDA falls into.



POINT Biopharma Global EV-to-EBITDA Calculation

POINT Biopharma Global's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1003.615/110.374
=9.09

POINT Biopharma Global's current Enterprise Value is $1,003.6 Mil.
POINT Biopharma Global's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $110.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


POINT Biopharma Global  (NAS:PNT) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

POINT Biopharma Global's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=12.50/1.100
=11.36

POINT Biopharma Global's share price for today is $12.50.
POINT Biopharma Global's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.100.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


POINT Biopharma Global EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of POINT Biopharma Global's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


POINT Biopharma Global (POINT Biopharma Global) Business Description

Traded in Other Exchanges
N/A
Address
4850 West 78th Street, Indianapolis, IN, USA, 46268
POINT Biopharma Global Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Its product pipeline includes PNT2002; PNT2004; PNT2003; PNT2001 and others.
Executives
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bridget A Martell director C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Joe A. Mccann director, officer: Chief Executive Officer 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Rajesh Malik director 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Gerald L. Hogue director 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
David Charles Lubner director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472

POINT Biopharma Global (POINT Biopharma Global) Headlines